Latest Partnerships News

Atomo Diagnostics capitalises on Lumos Diagnostics’ FebriDx FDA CLIA waiver with over $2 million in new sales orders and a $3 million capital raise, expanding its global footprint and product pipeline.

Axtec Limited has sold its PaySure loan book to Real Flow and secured a minority stake in the fintech, marking a strategic shift towards a platform-focused, AI-driven distribution model.

Amplia Therapeutics reported mature ACCENT trial data showing improved survival and multiple complete responses with narmafotinib, alongside a GMP production milestone and CFO appointment.

Nexsen Limited has cleared a major FDA regulatory hurdle for its StrepSure rapid Group B Streptococcus test, confirmed a clear 510(k) submission pathway, and secured over A$1.7 million in non-dilutive grants to expand clinical validation and market rollout in Asia-Pacific and neonatal diagnostics.

Xamble Group stabilised revenue at A$1.64 million in Q1 2026 while narrowing its group EBITDA loss slightly despite ramped-up technology spending. The company completed its acquisition of YouthsToday, tripling its influencer base and locking in three commercial contracts worth A$1.17 million.

Entropy Neurodynamics has reported encouraging early clinical outcomes from its pioneering intravenous psilocin therapy for Binge Eating Disorder, alongside a patent grant that strengthens its intellectual property moat.

Red Metal Limited is progressing key rare earth and base metal projects across Australia, securing government grants and proposing a major Maronan Metals share distribution to shareholders.

Australis Oil & Gas has partnered with a major US-listed company to develop its Tuscaloosa Marine Shale assets, retaining a 10% interest in producing wells and holding a strong cash position after recent transactions.

Emyria reported $1.2 million revenue for Q1 2026 driven by insurer-funded clinics and expanded its Empax network across multiple states. It launched a Global Partnership Program targeting international drug sponsors, leveraging its clinical infrastructure amid growing global interest in psychedelic therapies.

Chilwa Minerals confirmed a significant niobium discovery at its Nakombe target, progressing with dual diamond rig drilling and advancing a NASDAQ listing application. Heavy mineral sands resource work continues alongside a new ionic clay rare earth program.

AusQuest has confirmed a vast copper-gold system at its Cangallo project in Peru, revealing broad mineralisation and multiple higher-grade zones. Meanwhile, exploration momentum continues in Australia under a South32 alliance, with key drilling programs poised to start.

Cambium Bio has clinched FDA agreement on a streamlined single pivotal Phase 3 trial for Elate Ocular®, cutting development complexity, while bolstering its cash position through a A$2.4 million strategic placement by major shareholder ZYBT.